



US009192570B2

(12) **United States Patent**
Wyse et al.

(10) **Patent No.:** **US 9,192,570 B2**
(45) **Date of Patent:** **Nov. 24, 2015**

(54) **INTRANASAL NALOXONE COMPOSITIONS AND METHODS OF MAKING AND USING SAME**

(71) Applicant: **AntiOp, Inc.**, Lexington, KY (US)

(72) Inventors: **Joseph Wyse**, Nicholasville, KY (US);
Michael Paul DeHart, Winterville, NC (US)

(73) Assignee: **AntiOp, Inc.**, Lexington, KY (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/576,357**

(22) Filed: **Dec. 19, 2014**

(65) **Prior Publication Data**

US 2015/0174061 A1 Jun. 25, 2015

Related U.S. Application Data

(60) Provisional application No. 61/918,802, filed on Dec. 20, 2013.

(51) **Int. Cl.**

A61K 31/70 (2006.01)
A61K 9/00 (2006.01)
A61K 31/485 (2006.01)
A61K 47/10 (2006.01)
A61K 47/12 (2006.01)
A61K 47/18 (2006.01)

(52) **U.S. Cl.**

CPC **A61K 9/0043** (2013.01); **A61K 31/485** (2013.01); **A61K 47/10** (2013.01); **A61K 47/12** (2013.01); **A61K 47/183** (2013.01)

(58) **Field of Classification Search**

USPC 514/23
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,181,726 A 1/1980 Bernstein
4,464,378 A 8/1984 Hussain
5,482,965 A 1/1996 Rajadhyaksha
5,622,657 A 4/1997 Takada et al.
5,733,572 A 3/1998 Unger et al.
5,866,154 A * 2/1999 Bahal et al. 424/423
5,908,825 A 6/1999 Fasano et al.
5,958,962 A 9/1999 Cook
6,284,765 B1 9/2001 Caffrey
6,359,111 B1 3/2002 Meyer et al.
6,436,950 B1 8/2002 Achari et al.
6,716,449 B2 4/2004 Oshlack et al.
6,776,978 B2 8/2004 Rabinowitz et al.
6,969,508 B2 11/2005 Dugger
7,078,018 B2 7/2006 Rabinowitz et al.
7,090,830 B2 8/2006 Hale et al.
7,501,434 B2 3/2009 Shah et al.
7,563,899 B2 7/2009 Boyd et al.
7,745,665 B2 6/2010 Gant et al.
7,872,013 B2 1/2011 Gant et al.
7,910,599 B2 3/2011 Sinclair

7,915,285 B2 3/2011 Johnson et al.
7,964,183 B2 6/2011 Eliaz et al.
8,034,825 B2 10/2011 Bentley et al.
8,063,059 B2 11/2011 Hermann
8,247,425 B2 * 8/2012 Bazhina et al. 514/282
8,263,618 B2 9/2012 Long et al.
8,337,817 B2 12/2012 Nagata et al.
8,343,992 B2 1/2013 Doshan et al.
8,383,129 B2 2/2013 Mariscal-Gonzalez et al.
8,512,727 B2 8/2013 Cooper et al.
8,530,463 B2 9/2013 Cartt et al.
8,627,816 B2 1/2014 Edwards et al.
8,710,069 B2 4/2014 Holtman et al.
8,710,070 B2 4/2014 Holtman et al.
8,784,872 B2 7/2014 Oronsky et al.
8,889,635 B2 11/2014 Baker, Jr. et al.
2003/0077300 A1 4/2003 Wermeling
2003/0191147 A1 10/2003 Sherman et al.
2004/0102440 A1 5/2004 Wong
2004/0105881 A1 6/2004 Cevc et al.
2004/0142959 A1 7/2004 Jackson
2004/0167146 A1 8/2004 Jackson
2004/0180916 A1 9/2004 Levine
2005/0008707 A1 1/2005 Hovey et al.
2005/0038062 A1 2/2005 Burns et al.
2005/0126562 A1 6/2005 Rabinowitz et al.
2005/0214223 A1 9/2005 Bartholomaeus et al.
2005/0222135 A1 10/2005 Buschmann et al.
2005/0233001 A1 10/2005 Hovey et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CN 1 575 795 A 2/2005
CN 1 726 915 A 2/2006
CN 101036651 A 9/2007
EP 0 880 352 B1 2/1998
EP 1 810 670 A1 7/2007
EP 2 266 563 12/2010
RU 2 344 822 1/2009
WO WO 82/03768 11/1982
WO WO 93/24164 12/1993
WO WO 98/30211 7/1998
WO WO 99/11250 3/1999
WO WO 00/62757 10/2000
WO WO 00/74652 12/2000
WO WO 2005/020906 3/2005
WO WO 2008/139170 11/2008
WO WO 2009/040595 4/2009
WO WO 2009/049233 4/2009
WO WO 2011/144746 11/2011
WO WO 2012/156317 11/2012

OTHER PUBLICATIONS

International Search Report and Written Opinion dated Mar. 11, 2015 for Application No. PCT/US2014/071371.

(Continued)

Primary Examiner — Rei-Tsang Shiao

(74) *Attorney, Agent, or Firm* — Frost Brown Todd LLC

(57)

ABSTRACT

Disclosed herein are compositions containing an opioid antagonist such as naloxone and one or more pharmaceutically acceptable excipients. The compositions may be used for intranasal delivery of Naloxone for the treatment of, for example, opioid overdose in an individual in need thereof. Also disclosed are methods of making compositions containing Naloxone, and devices for nasal delivery of naloxone compositions.

15 Claims, 5 Drawing Sheets

(56)

References Cited

U.S. PATENT DOCUMENTS

2005/0245483 A1 11/2005 Brogmann et al.
 2005/0245556 A1 11/2005 Brogmann et al.
 2006/0009478 A1 1/2006 Friedmann et al.
 2006/0110333 A1 5/2006 Yanagawa
 2006/0111382 A1 5/2006 Shafer et al.
 2006/0120962 A1 6/2006 Rabinowitz et al.
 2006/0120967 A1 6/2006 Namburi et al.
 2007/0071806 A1 3/2007 McCarty
 2007/0082893 A1 4/2007 Buschmann et al.
 2007/0212307 A1 9/2007 Wermeling et al.
 2008/0026052 A1 1/2008 Schoenhard
 2008/0066741 A1 3/2008 LeMahieu et al.
 2008/0078382 A1 4/2008 LeMahieu et al.
 2008/0145429 A1 6/2008 Leyendecker et al.
 2008/0146549 A1 6/2008 Coleman
 2008/0152595 A1 6/2008 Emigh et al.
 2008/0171762 A1 7/2008 Ockert
 2008/0176884 A1 7/2008 Perez et al.
 2008/0207669 A1 8/2008 Perez et al.
 2008/0234306 A1 9/2008 Perez et al.
 2009/0041687 A1 2/2009 Beumer et al.
 2009/0041800 A1 2/2009 Woiwode et al.
 2009/0047279 A1 2/2009 Perez et al.
 2009/0111741 A1 4/2009 Aldrich et al.
 2009/0246256 A1 10/2009 Al-Ghananeem
 2009/0297611 A1 12/2009 Robinson et al.
 2010/0041689 A1 2/2010 Johnson et al.
 2010/0087337 A1 4/2010 Dewitt
 2010/0143449 A1 6/2010 Kolesnikov
 2010/0144645 A1 6/2010 Kirk et al.
 2010/0168147 A1 7/2010 Chapleo et al.
 2010/0221339 A1 9/2010 Hermann
 2010/0222257 A1 9/2010 Gant et al.
 2010/0226989 A1 9/2010 Hovey et al.
 2010/0286186 A1 11/2010 Franklin et al.
 2010/0294268 A1 11/2010 Wensley et al.
 2010/0311691 A1 12/2010 Barkan et al.
 2010/0331354 A1 12/2010 Wermeling
 2011/0033544 A1 2/2011 Nagata et al.
 2011/0059117 A1 3/2011 Seigfried
 2011/0065628 A1 3/2011 Johnson et al.
 2011/0105551 A1 5/2011 Birch et al.
 2012/0040009 A1 2/2012 Hermann
 2012/0270895 A1 10/2012 Wermeling
 2013/0059876 A1 3/2013 Angeli et al.
 2014/0171458 A1 6/2014 Brown et al.
 2015/0258019 A1 9/2015 Crystal et al.

OTHER PUBLICATIONS

Anonymous: "Narcan", Drugs.com, print version, Jan. 1, 2006, www.drugs.com/pro/narcan.html?printable=1, retrieved Feb. 19, 2015.
 Albert, S., et al., "Project Lazarus: Community-Based Overdose Prevention in Rural North Carolina", Pain Medicine, 2011, 12:S77-S85.
 Alexander, MD, J. L., et al., "Suspected Opioid-Related Emergency Medical Services Encounters in a Rural State, 1997-2002", Prehospital Emergency Care, Oct./Dec. 2004, vol. 8, No. 4, pp. 427-430.
 Ashworth, A.J., et al., "Take home naloxone for opiate addicts: Apparent advantages may be balanced by hidden harms", BMJ, vol. 323, Oct. 20, 2001, p. 935.
 Aurora, MD, J., "Development of Nasal Delivery Systems: A Review", Drug Development & Delivery, Oct. 2002, vol. 2, No. 7, 5 pgs.
 Barton, MD, MS; E.D., et al., "Intranasal Administration of Naloxone by Paramedics", Prehospital Emergency Care, Jan./Mar. 2002;6(1):54-8.
 Barton, MD, E.D., et al., "Efficacy of Intranasal Naloxone as a Needless Alternative for Treatment of Opioid Overdose in the Prehospital Setting", The Journal of Emergency Medicine, vol. 29, No. 3, pp. 265-271, 2005.

Baumann, MD, B.M., et al., "Use and efficacy of nebulized naloxone in patients with suspected opioid intoxication", American Journal of Emergency Medicine, vol. 31, 2013, pp. 585-588.
 Beletsky, L., et al., "Physicians' Knowledge of and Willingness to Prescribe Naloxone to Reverse Accidental Opiate Overdose: Challenges and Opportunities", Journal of Urban Health: Bulletin of the New York Academy of Medicine, vol. 84, No. 1, 2006, pp. 126-136.
 Beletsky, L., et al., Closing Death's Door: Action Steps to Facilitate Emergency Opioid Drug Overdose Reversal in the United States A Conference Report from the Center for Health Law, Politics and Policy Temple University Beasley School of Law, 2009.
 Belz, BA, D., et al., "Naloxone Use in a Tiered-Response Emergency Medical Services System", Prehospital Emergency Care, Oct.-Dec. 2006; 10, 4, pp. 468-471.
 Bernstein, J.A., et al., "Double-blind placebo-controlled trial of reformulated azelastine nasal spray in patients with seasonal allergic rhinitis", Am J Rhinol Allergy, 2009, vol. 23, pp. 512-517. Abstract only.
 Bristol-Myers Squibb. Butorphanol tartrate nasal spray prescribing information 2002, 11 pgs.
 Blackwood, G., "Take home naloxone for opiate addicts: Figures in Jersey give no support to scheme's effectiveness", BMJ, vol. 323, Oct. 20, 2001, pp. 934-935.
 Bohnert, ASB, et al., "Association Between Opioid Prescribing Patterns and Opioid Overdose-Related Deaths", JAMA, 2011, 305(13):1315-1321.
 Boyd, J.J., et al., "Recurrent opioid toxicity after pre-hospital care of presumed heroin overdose patients", Acta Anaesthesiol Scand, 2006; 50:1266-1270.
 Bracken, M.B., et al., "A Randomized, Controlled Trial of Methylprednisolone or Naloxone in the Treatment of Acute Spinal Cord Injury—Results of the Second National Acute Spinal Cord Injury Study", N Engl J Med, 322:1405-1411, 2009.
 Buajordet, I., et al., "Adverse events after naloxone treatment of episodes of suspected acute opioid overdose", European Journal of Emergency Medicine, 2004, vol. 11, No. 1, p. 19-23.
 Burris, S., et al., "Legal Aspects of Providing Naloxone to Heroin users in the United States", International Journal of Drug Policy, 2001; 12:237-248.
 Burris, S., et al., "Stopping an Invisible epidemic: Legal Issues in the Provision of Naloxone to Prevent Opioid Overdose", Drexel Law Review, 2009, 1(2):273-339.
 Cantwell, K., et al., "The relationship between naloxone dose and key patient variables in the treatment of non-fatal heroin overdose in the prehospital setting", Resuscitation, 2005, vol. 65, pp. 315-319.
 Centers for Disease Control and Prevention, National Center for Health Statistics. Deaths: preliminary data for 2009, Natl Vital Stat Rep., 2011; 59:17-20.
 Centers for Disease Control and Prevention, Morbidity and Mortality Weekly Report. Vital signs: overdoses of prescription opioid pain relievers—United States, 1999-2008. Nov. 4, 2011; 60(43):1487-1492.
 Centers for Disease Control and Prevention, "Emergency department visits involving nonmedical use of selected prescription drugs—United States, 2004-2008", MMWR Morbidity and mortality weekly report 2010;59(23):705-9.
 City and County of San Francisco, Department of Public Health, "Naloxone Training for providers", Nov. 8, 2012, pp. 1-9.
 Clark, et al., "A Systematic Review of Community Opioid Overdose Prevention and Naloxone Distribution Programs" J Addict Med, May/Jun. 2014, vol. 8, No. 3, pp. 153-163.
 Clark, SFJ, et al., "Naloxone in Opioid Poisoning: Walking the Tight-rop", Emerg Med J 2005, 222:612-616.
 Coda, MD, B.A., et al., "Pharmacokinetics and Bioavailability of Single-Dose Intranasal Hydromorphone Hydrochloride in Healthy Volunteers", Anesth Analg. 2003; 97:117-23.
 Compton, MD, MPE, W.M., et al., "Expanded Access to Opioid Overdose Intervention: Research, Practice, and Policy Needs", Annals of Internal Medicine, Jan. 1, 2013, vol. 158, No. 1, pp. 65-66.
 Costantino, H.R, et al. "Intranasal delivery: Physicochemical and therapeutic aspects", Int J Pharm, 2007; 337:1-24.
 Dale, O., et al., "Nasal administration of opioids for pain management in adults", Acta Anaesthesiol Scand. 2002; 46:759-70.

(56)

References Cited

OTHER PUBLICATIONS

- Doe-Simkins, M., et al., "Saved by the Nose: Bystander-Administered Intranasal Naloxone Hydrochloride for Opioid Overdose", *American Journal of Public Health*, May 2009, vol. 99, No. 5, pp. 788-791.
- Dowling, et al., "Population Pharmacokinetics of Intravenous, Intramuscular, and Intranasal Naloxone in Human Volunteers," *Therapeutic Drug Monitoring*, 30(4):490-496 (2008).
- Drug Abuse Warning Network, The DAWN Report, Highlights of the 2010 Drug Abuse Warning Network (DAWN) Findings on Drug-Related Emergency Department Visits, Jul. 2, 2012, pp. 1-8.
- FDA Draft Guidance for Industry and Food and Drug Administration Staff—Applying Human Factors and Usability Engineering to Optimize Medical Device, Jun. 22, 2011, pp. 1-37.
- FDA Guidance for Industry, "Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products—Chemistry Manufacturing, and Controls Documentation", Jul. 1, 2002, pp. 1-49.
- Fernandez, MD, MPH, W., et al., "Trends in opioid-related fatal overdoses in Massachusetts, 1990-2003", *J Subst Abuse Treat.* 2006; 31:151-6.
- Flamm, E.S., et al., "A Phase I trial of naloxone treatment in acute spinal cord injury", *Journal of Neurosurgery*, Sep. 1985, vol. 63, No. 3, pp. 390-397.
- Gaston, R. L., et al., "Can we prevent drug related deaths by training opioid users to recognise and manage overdoses?", *Harm Reduction Journal*, 2009, 6:26, 35 pgs.
- Graham, C.A., et al. "Take home naloxone for opiate addicts: Drug misusers may benefit from training in cardiopulmonary resuscitation", *BMJ*, vol. 323, Oct. 20, 2001, p. 934.
- Hall, DVM, MSPH, A.J., et al., "Patterns of Abuse Among Unintentional Pharmaceutical Overdose Fatalities", *JAMA*, Dec. 10, 2008, vol. 300, No. 22, pp. 2613-2620.
- Havens, J.R., et al., "Prevalence of opioid analgesic injection among rural nonmedical opioid analgesic users", *Drug Alcohol Depend.* 2007; 87:98-102.
- Heard, MD, C., et al., "Case report: Intranasal flumazenil and naloxone to reverse over-sedation in a child undergoing dental restorations", *Pediatric Anesthesia*, 2009, vol. 19, pp. 795-799.
- Hewlett, PharmD, L., et al., "Survey of naloxone legal status in opioid overdose prevention and treatment", *Journal of Opioid Management*, Sep./Oct. 2013, vol. 5, No. 5, pp. 369-377.
- Hospira, Inc. Naloxone hydrochloride injection package insert. 2007.
- Hospira, Inc., Naloxone Hydrochloride injection solution, prescribing information, Nov. 2006.
- Hussain, A., et al., "Nasal absorption of naloxone and buprenorphine in rats", *Int Journal Pharm*, Sep. 1984, vol. 21, Issue 2, pp. 233-237.
- International Medication Systems L. Naloxone hydrochloride injection package insert. 2006.
- International Medication Systems, Limited, Naloxone Hydrochloride—naloxone hydrochloride injection, prescribing information, Aug. 2001.
- International Search Report dated Mar. 20, 2013 for Application No. PCT/EP2012/058792, 2012.
- International Preliminary Report on Patentability dated Nov. 19, 2013 for Application No. PCT/EP2012/058792, 2012.
- Jones, C.M., et al., "Pharmaceutical Overdose Deaths, United States, 2010", *JAMA* 2013;309:657-9.
- Kelly, A-M., "Intranasal naloxone for life threatening opioid toxicity", *Emergency Medicine Journal*, 2002; 19:14, 375.
- Kelly, A-M., et al., "Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose", *MJA*, Jan. 3, 2005, vol. 182, No. 1, pp. 24-27.
- Kentucky Science and Technology Corporation (KSTC), Grant Agreement No. KSTC-184-512-11-104, Naloxone Nasal Spray Administration, Patent and Business Plan Development, Alcomed, Inc., Feb. 1, 2011-Jan. 31, 2012, 16 pgs.
- Kentucky Science and Technology Corporation (KSTC), Grant Agreement No. KSTC-184-512-12-125, Naloxone Nasal Spray Development, Alcomed, Inc., Apr. 1, 2012-Mar. 31, 2013, 17 pgs.
- Kerr, D., et al., "Intranasal naloxone for the treatment of suspected heroin overdose", *Addiction*, 2008, vol. 103, pp. 379-386.
- Kerr, D., et al., "Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose", *Addiction*, 2009, vol. 104, pp. 2067-2074.
- Kim, MPH, D., et al., "Expanded Access to Naloxone: Options for Critical Response to the Epidemic of Opioid Overdose Mortality", *American Journal of Public Health*, Mar. 2009, vol. 99, No. 3, pp. 402-407.
- Loimer, M.D., N., et al., "Nasal Administration of Naloxone Is as Effective as the Intravenous Route in Opiate Addicts", *The International Journal of the Addictions*, 1994, vol. 29, No. 6, pp. 819-827.
- Loimer, N., et al., "Nasal Administration of Naloxone for Detection of Opiate Dependence", *J. Psychiat. Res.*, 1992, vol. 26, No. 1, pp. 39-43.
- Mack, PhD, K.A., et al., "Vital Signs: Overdoses of Prescription Opioid Pain Relievers and Other Drugs Among Women—United States, 1999-2010", *Centers for Disease Control and Prevention, Morbidity and Mortality Weekly Report, Early Release/vol. 62*, Jul. 2, 2013.
- Manchikanti, MD, L., et al., "Therapeutic Use, Abuse, and Nonmedical Use of Opioids: a Ten-Year Perspective", *Pain Phys.* 2010; 13:401-35.
- Marx, J., Ed. et al., *Rosen's Emergency Medicine*. 7th ed. St. Louis, MO; 2010.
- Merlin, DO, EMT-P, M.A., et al., "Intranasal naloxone delivery is an alternative to intravenous naloxone for opioid overdoses", *American Journal of Emergency Medicine*, 2010, vol. 28, pp. 296-303.
- Middleton, L.S., et al., "The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers", *Addiction*, 2011, vol. 106, pp. 1460-1473.
- Mountain, D., "Take home naloxone for opiate addicts: Big conclusions are drawn from little evidence", *BMJ*, vol. 323, Oct. 20, 2001, p. 934.
- Ngai, MD, S.H., et al., "Pharmacokinetics of Naloxone in Rats and in Man: Basis for Its Potency and Short Duration of Action", *Anesthesiology*, 1976; 44:398-401.
- Osterwalder, MD, MPH, J.J., "Naloxone—For Intoxications with Intravenous Heroin and Heroin Mixtures—Harmless of Hazardous? A Prospective Clinical Study", *Clin Toxicol.* 1996; 34:409-16.
- Paulozzi, L.J., et al., "US data show sharply rising drug-induced death rates", *Injury prevention journal of the International Society for Child and Adolescent Injury Prevention*, 2007;13:130-2.
- Paulozzi, MD, L.J., "Vital Signs: Variation Among States in Prescribing of Opioid Pain Relievers and Benzodiazepines—United States, 2012", *Centers for Disease Control and Prevention, Morbidity and Mortality Weekly Report, Early Release/vol. 63*, Jul. 1, 2014.
- Paulozzi, L., et al., "Prescription drug laws, drug overdoses, and drug sales in New York and Pennsylvania", *Journal of Public Health Policy*, 2010, vol. 31, No. 4, pp. 422-432.
- Piper, T.M., et al., "Overdose prevention for injection drug users: Lessons learned from naloxone training and distribution programs in New York City", *Harm Reduction Journal*, 2007;4:3, 8 pgs.
- Prescribe to Prevent: Prescribe Naloxone, Save a Life. (Accessed Jan. 1, 2013, at <http://www.prescribetoprevent.org/>) pp. 1-16.
- Project Lazarus: Community-based Overdose Prevention with North Carolina and the Community Care Chronica Pain Initiative, Available at <http://projectlazarus.org/>, Accessed Jul. 19, 2012, pp. 1-42.
- Richardson, MD, J., "Lexington—Fayette Urban County Government Division of Fire & Emergency Services", Jul. 1, 2007.
- Robertson, T.M., et al., "Intranasal Naloxone Is a Viable Alternative to Intravenous Naloxone for Prehospital Narcotic Overdose", *Prehospital emergency care : official journal of the National Association of EMS Physicians and the National Association of State EMS Directors* 2009;13:512-5.
- Rudy, PhD, A.C., et al., "A Multiple-Dose Phase I Study of Intranasal Hydromorphone Hydrochloride in Healthy Volunteers", *Ambulatory Anesthesia*, 2004; 99:1379-86.

(56)

References Cited


OTHER PUBLICATIONS

- Seal, K.H., et al., "Predictors and Prevention of Nonfatal Overdose Among Street-Recruited Injection Heroin Users in the San Francisco Bay Area, 1998-1999", *American Journal of Public Health* 2001; 91:1842-6.
- Seal, K.H., et al., "Naloxone Distribution and Cardiopulmonary Resuscitation Training for Injection Drug Users to Prevent Heroin Overdose Death: A Pilot Intervention Study", *J Urban Health*, Jun. 2005, 82(2):303-311.
- Seigler, A. et al. "Unintentional opioid overdose deaths in New York City, 2005-2010: A place-based approach to reduce risk", *International Journal of Drug Policy*, May 2014;25(3):569-74.
- Shah, N.G., et al., "Unintentional drug overdose death trends in New Mexico, USA, 1990-2005: combinations of heroin, cocaine, prescription opioids and alcohol", *Addiction*. 2007; 103:126-36.
- Sherman, S.G., et al. "The life they save may be mine: Diffusion of overdose prevention information from a city sponsored programme", *International Journal of Drug Policy*, 2009; 20:137-42.
- Sporer, K.A., et al., "Out-of-hospital Treatment of Opioid Overdoses in an Urban Setting", *Academic Emergency Medicine*, Jul. 1996, vol. 3, No. 7, 660-7.
- Sporer, K.A., et al., "Prescription Naloxone: A Novel Approach to Heroin Overdose Prevention", *Annals of Emergency Medicine*, Feb. 2007; vol. 49, No. 2, pp. 172-177.
- Strang, J., "Take home naloxone for opiate addicts: Author's reply", *BMJ*, vol. 323, Oct. 20, 2001, p. 935.
- Vilke GM, et al., "Are heroin overdose deaths related to patient release after prehospital treatment with naloxone?", *Prehosp Emerg Care*. 1999; 3:183-6.
- Vilke, MD, G.M., et al., "Assessment for Deaths in Out-of-hospital Heroin Overdose Patients Treated with Naloxone Who Refuse Transport", *Acad Emerg Med*. 2003; 10:893-6.
- Walley, A.Y., et al., "Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis", *BMJ*, 2013; 346:f174.
- Wahlh ufer, K.H., "Die mikrobielle Kontamination von Kosmetika Rohstoffe—Produktion—Konservierung", *Parf merie und Kosmetik*, 53. Jahrgang, Nr. 11/1972. German Language only.
- Wanger, K., et al., "Intravenous vs subcutaneous naloxone for out-of-hospital management of presumed opioid overdose", *Academic emergency medicine : official journal of the Society for Academic Emergency Medicine*, 1998;5:293-9.
- Warner, M., et al., "Drug poisoning deaths in the United States, 1980-2008", *NCHS data brief*, No. 81. Hyattsville, MD: National Center for Health Statistics. 2011.
- Warner, PhD, M., et al., "Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006", *NCHS data brief*, 2009:1-8.
- Warner, PhD, M., et al., "Trends in Drug-poisoning Deaths Involving Opioid Analgesics and Heroin: United States, 1999-2012", *NCHS data brief*, Dec. 2014.
- Wermeling, PharmD, D.P., et al., "Pharmacokinetics, Bioequivalence, and Spray Weight Reproducibility of Intranasal Butorphanol After Administration With 2 Different Nasal Spray Pumps", *J Clin Pharmacol*. 2005; 45:969-73.
- Wermeling, D.P., et al., "A Multicenter, Open-Label, Exploratory Dose-Ranging Trial of Intranasal Hydromorphone for Managing Acute Pain from Traumatic Injury", *J Pain*. 2010; 11:24-31.
- Wermeling, D.P., "Opioid Harm Reduction Strategies: Focus on Expanded Access to Intranasal Naloxone", *Pharmacotherapy*, 2010; 30(7):627-31.
- Wermeling, D.P., "A response to the opioid overdose epidemic: naloxone nasal spray", *Drug Deliv. and Transl. Res.*, Aug. 1, 2012.
- Wheeler, E, et al., "Community-Based Opioid Overdose Prevention Programs Providing Naloxone—United States, 2010", *Centers for Disease Control and Prevention, Morbidity and Mortality Weekly Report*, vol. 61, No. 6, Feb. 17, 2012, pp. 101-105.
- Yealy, D.M., et al., "The Safety of Prehospital Naloxone Administration by Paramedics", *Ann Emerg Med.*, Aug. 1990, vol. 19, No. 8, pp. 902-905.
- Yokell, ScB, M.A., et al., "Opioid Overdose Prevention and Naloxone Distribution in Rhode Island", *Med Health R.I.*, Aug. 2011; 94(8):240-242.
- Yokell, ScB, M.A., et al., "Presentation of Prescription and Nonprescription Opioid Overdoses to US Emergency Departments", *JAMA Internal Medicine*, Oct. 27, 2014.
- Behl, C.R., et al., "Effect of physicochemical properties and other factors on systemic nasal drug delivery", *Advanced Drug Delivery Reviews*, 1998, 29:89-116, 28 pgs.
- US Office Action dated Feb. 12, 2015 for U.S. Appl. No. 13/494,882, 8 pgs.

* cited by examiner

FIG 1

Analyte=Naloxone



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.